Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy

Inclusion Criteria: Subjects meeting the following criteria will be eligible for enrollment in the study (unless excluded): * ≥60 years old * Pathologically confirmed NHL. * Must meet criteria for initiation of treatment; consisting of: * Aggressive histology, or * Indolent histology with one of the following markers of large tumor burden (67): * Any nodal or extranodal tumor mass ≥7cm in greatest dimension * ≥3 nodal masses that are each ≥3 cm in greatest dimension * Systemic symptoms * Cytopenias (leukocytes \<1 × 109/L and/or platelets ,100 × 109/L) * Substantial splenomegaly * Serous effusion (plural effusion or peritoneal ascites) * Orbital or epidural involvement * Ureteral compression * Leukemic phase (malignant cells ≥5 x 109/L) * Must be starting a new chemotherapy regimen (patients whose treatment regimen includes an immunomodulatory agent such as lenalidomide or small molecule targeted agents such as Ibrutinib or Idelelasib will be included in the study; patients being treated with a single agent monoclonal antibody will not be included). * Fluent in English (because not all components of the GA have been validated in other languages) * Able to provide informed consent In addition to the above, subjects meeting the following criteria will be enrolled in the pre-phase arm of the study, until the accrual target for that arm is reached: * Age ≥ 70 years OR KPS ≤ 70 * Pathologically confirmed diagnosis of DLBCL, with or without simultaneous or antecedent indolent l…